Compugen Expands and Strengthens Business Development Team
News Mar 10, 2015
Compugen Ltd. has announced the appointment of Dr. Felix Karim as Vice President Corporate & Business Development, effective March 2, 2015. Dr. Karim, who will be based at Compugen’s South San Francisco facilities, will report to Dr. Anat Cohen-Dayag, Compugen’s President and Chief Executive Officer, and will have direct responsibility for the Company’s business development strategy and its execution.
Dr. Cohen-Dayag, President and CEO of Compugen, stated, “We are very pleased to welcome Felix to Compugen’s senior management team. Felix brings to Compugen substantial experience and accomplishments in a range of biopharma companies, from start-ups to leading public companies, initially as a senior scientist and project leader, and later as an executive with broad responsibilities in both R&D and business development. We are excited to have the benefit of his experience and capabilities as we evaluate a number of potential collaboration options to maximize the value of our attractive early stage target pipeline and our unique, broadly applicable predictive discovery capabilities.”
Dr. Karim has significant experience in the biopharmaceutical industry and has held various executive roles in business development and R&D management. His most recent position prior to joining Compugen was Head of External R&D (licensing) for the San Francisco region at Amgen.
Before Amgen, Dr. Karim was Vice President of Business Development at KAI Pharmaceuticals, where he led business development and transaction activities, including the sale of KAI Pharmaceuticals to Amgen.
Dr. Karim has also held various positions at Exelixis and Celera Genomics, leading multidisciplinary teams across a broad range of activities in R&D and program development, and has played an integral role in business development efforts that resulted in significant pharma partnerships.
Dr. Karim holds a bachelor’s degree in biochemistry from the University of California, Berkeley, and a PhD from the Department of Human Genetics at the University of Utah Medical School.
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Comments | 0 ADD COMMENT
7th International Conference on Bacteriology and Infectious Diseases
Jun 04 - Jun 05, 2018